Related Experiment Video
Updated: Aug 23, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Comprehensive Analysis and Functional Characteristics of Differential Expression of N6-Methyladenosine Methylation
Lei Wan1,2, Jian Liu1,2, Chuanbing Huang1
1The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230038, China.
Abstract:
N6-methyladenosine (m6A) modification is the most prevalent chemical modification in eukaryotic mRNA and is associated with the development of various immune diseases. However, the role of m6A methylation in rheumatoid arthritis (RA) development is unclear. We preliminarily explored the role of m6A methylation-related mRNAs in RA for its clinical application. The discovery of m6A methylation-modifying genes in this study may provide a fresh perspective on the development of drugs for RA treatment. High-throughput sequencing combined with methylated RNA immunoprecipitation (MeRIP-seq) and RNA sequencing were used to assess whole-transcriptome m6A modifications in the synovium of patients with RA. The relationship between m6A-modified target genes and RA inflammation and macrophages was determined. The expression of the m6A-modified significant transcript-enriched inflammatory signaling pathway was assessed through animal experiments. Differentially expressed m6A genes were correlated with macrophage activation involved in immune response, vascular endothelium, MAPK signaling pathway, PI3K - Akt signaling pathway, and other inflammatory processes. Furthermore, combined analysis with m6A-seq and RNA-seq revealed 120 genes with significant changes in both m6A modification and mRNA expression. We selected the top 3 candidate mRNAs that were upregulated and downregulated simultaneously. The expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) mRNA and protein in RA patients was lower than that in healthy control (HC). SHC-binding protein 1 (SHCBP1) and neurexophilin-3 (NXPH3) mRNA expressions were increased in RA patients. The expression of M1 macrophages was increased in RA patients. RA markers are such as rheumatoid factor (RF) and peptide containing citrulline (CCP). Further animal experiments showed that the expression of synovial MAPK, PI3K, and Akt1 proteins in the RA model was increased, and the PTEN, p-PTEN protein expression was decreased. PI3K, Akt1, PTEN, and p-PTEN were correlated to RA joint inflammation. This study revealed a unique pattern of differential m6A methylation modifications in RA and concluded that m6A modification is related to the occurrence of RA synovial inflammation.
Insights
N6-methyladenosine (m6A) modification plays a role in rheumatoid arthritis (RA) development. This study identified key m6A-modified genes and pathways involved in RA synovial inflammation, offering potential therapeutic targets.
Area of Science:
- Epigenetics and Molecular Biology
- Immunology and Rheumatology
Background:
- N6-methyladenosine (m6A) is the most common mRNA modification in eukaryotes, linked to immune diseases.
- The specific role of m6A methylation in rheumatoid arthritis (RA) pathogenesis remains largely unexplored.
Purpose of the Study:
- To investigate the role of m6A methylation-related messenger RNAs (mRNAs) in RA development.
- To identify potential clinical applications and therapeutic targets for RA treatment based on m6A modification.
Main Methods:
- Utilized high-throughput sequencing, methylated RNA immunoprecipitation (MeRIP-seq), and RNA sequencing (RNA-seq) on synovial tissue from RA patients.
- Analyzed the correlation between m6A-modified genes, RA inflammation, macrophage activation, and signaling pathways (MAPK, PI3K-Akt).
- Validated findings through animal experiments assessing m6A modification patterns and protein expression in an RA model.
Main Results:
- Identified 120 genes with significant changes in both m6A modification and mRNA expression in RA.
- Observed decreased expression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) mRNA and protein in RA patients.
- Found increased expression of SHC-binding protein 1 (SHCBP1) and neurexophilin-3 (NXPH3) mRNA, alongside elevated M1 macrophages and activated MAPK/PI3K-Akt signaling in RA.
Conclusions:
- Revealed a distinct pattern of differential m6A methylation in RA synovial tissue.
- Concluded that m6A modification is significantly associated with the occurrence and progression of RA synovial inflammation.
- Highlighted m6A-modifying genes as potential novel therapeutic targets for RA treatment.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
RNA Editing
The JAK-STAT Signaling Pathway

